JP2022172244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022172244A5 JP2022172244A5 JP2022137454A JP2022137454A JP2022172244A5 JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5 JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hcv
- genotype
- hcv genotype
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (11)
- 以下を含む、免疫原性組成物:
(a)第1のC型肝炎ウイルス(HCV)遺伝子型からのHCV E1ポリペプチド、E2ポリペプチド、またはE1/E2ヘテロ二量体ポリペプチド、ここで、該第1のHCV遺伝子型は遺伝子型1型である;
(b)第2のHCV遺伝子型からのHCV E1ポリペプチド、E2ポリペプチド、またはE1/E2ヘテロ二量体ポリペプチド、ここで、該第2のHCV遺伝子型は遺伝子型3型である;
(c)薬学的に許容される賦形剤;および
(d)免疫刺激量のアジュバント、
ここで、該組成物は、HCV遺伝子型1型およびHCV遺伝子型3型以外の遺伝子型のHCV E1/E2ヘテロ二量体ポリペプチド、E1ポリペプチド、またはE2ポリペプチドを含まない。 - 前記E1ポリペプチドが可溶性E1ポリペプチドである、請求項1に記載の免疫原性組成物。
- 前記E1ポリペプチドが全長E1ポリペプチドである、請求項1に記載の免疫原性組成物。
- 前記E2ポリペプチドが可溶性E2ポリペプチドである、請求項1に記載の免疫原性組成物。
- 前記E2ポリペプチドが全長E2ポリペプチドである、請求項1に記載の免疫原性組成物。
- (i)HCV遺伝子型1型のE1/E2ヘテロ二量体ポリペプチド;及びHCV遺伝子型3型のE1/E2ヘテロ二量体ポリペプチド;または
(ii)HCV遺伝子型1型の可溶性E2ポリペプチド;およびHCV遺伝子型3型の可溶性E2ポリペプチド;または
(iii)HCV遺伝子型1型の可溶性E1ポリペプチドおよび可溶性E2ポリペプチド;ならびに、HCV遺伝子型3型の可溶性E1ポリペプチドおよび可溶性E2ポリペプチド
を含む、請求項1に記載の免疫原性組成物。 - 前記アジュバントが、MF59、ミョウバン、モノホスホリル脂質A、コレステロール、Quil A、またはCpGオリゴヌクレオチドを含む、請求項1に記載の免疫原性組成物。
- 前記HCV E1ポリペプチド、E2ポリペプチド、またはE1/E2ヘテロ二量体ポリペプチドが少なくとも90%純粋である、請求項1に記載の免疫原性組成物。
- 個体においてC型肝炎ウイルス(HCV)に対する免疫応答を誘導する方法において使用するための請求項1~8のいずれか1項に記載の組成物であって、該免疫応答がHCV遺伝子型1型および3型に対する中和抗体の産生を含む、該組成物。
- 筋肉内に投与される、請求項9に記載の組成物。
- 前記個体が静注薬物使用者である、請求項9に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361823712P | 2013-05-15 | 2013-05-15 | |
US61/823,712 | 2013-05-15 | ||
US201361887229P | 2013-10-04 | 2013-10-04 | |
US61/887,229 | 2013-10-04 | ||
JP2021001926A JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | E1e2 hcvワクチン及び使用方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021001926A Division JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | E1e2 hcvワクチン及び使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022172244A JP2022172244A (ja) | 2022-11-15 |
JP2022172244A5 true JP2022172244A5 (ja) | 2023-07-28 |
Family
ID=54054625
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | E1e2hcvワクチン及び使用方法 |
JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | E1e2 hcvワクチン及び使用方法 |
JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | E1e2 hcvワクチン及び使用方法 |
JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | E1e2 hcvワクチン及び使用方法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | E1e2hcvワクチン及び使用方法 |
JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | E1e2 hcvワクチン及び使用方法 |
JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | E1e2 hcvワクチン及び使用方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20210145963A9 (ja) |
EP (2) | EP3689375A1 (ja) |
JP (4) | JP2016520077A (ja) |
CN (2) | CN105263517B (ja) |
AU (3) | AU2014385320B2 (ja) |
CA (1) | CA2909586C (ja) |
CL (1) | CL2015003333A1 (ja) |
HK (1) | HK1216395A1 (ja) |
WO (1) | WO2015132619A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3000313A1 (en) * | 2015-10-08 | 2017-04-13 | The Governors Of The University Of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
CA3037813A1 (en) * | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
US10881726B2 (en) | 2016-10-11 | 2021-01-05 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
EP3765075A4 (en) * | 2018-03-16 | 2021-12-08 | The Governors of the University of Alberta | PEPTIDIC COMPOSITIONS OF THE HEPATITIS C VIRUS AND THEIR USE PROCEDURES |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
WO1996004301A2 (en) | 1994-07-29 | 1996-02-15 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
ATE437951T1 (de) | 1997-05-06 | 2009-08-15 | Novartis Vaccines & Diagnostic | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
ES2326848T3 (es) | 1997-06-06 | 2009-10-20 | The Regents Of The University Of California | Inhibidores de la actividad de secuencias inmunoestimulatorias de adn. |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
KR20010042573A (ko) | 1998-04-09 | 2001-05-25 | 장 스테판느 | 애쥬번트 조성물 |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
AU750587B2 (en) | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
JP4846906B2 (ja) | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
CN1391483A (zh) | 1999-09-24 | 2003-01-15 | 史密丝克莱恩比彻姆生物有限公司 | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 |
WO2001021152A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
CN1636015A (zh) * | 2001-06-29 | 2005-07-06 | 希龙公司 | Hcv e1e2疫苗组合物 |
US7348011B2 (en) * | 2005-06-10 | 2008-03-25 | Sudershan Biotech Ltd. | Hepatitis C virus vaccine |
WO2007041432A2 (en) * | 2005-09-30 | 2007-04-12 | Novartis Vaccines And Diagnostics, Inc. | Cross-neutralization of hcv with recombinant proteins |
US8603468B2 (en) * | 2007-11-06 | 2013-12-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Neutralization of HCV |
WO2014060851A2 (en) * | 2012-10-05 | 2014-04-24 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
-
2014
- 2014-05-15 CN CN201480027001.3A patent/CN105263517B/zh active Active
- 2014-05-15 CN CN202110252076.3A patent/CN112999344A/zh active Pending
- 2014-05-15 EP EP19215826.9A patent/EP3689375A1/en not_active Withdrawn
- 2014-05-15 EP EP14884476.4A patent/EP2996718B1/en active Active
- 2014-05-15 WO PCT/IB2014/001972 patent/WO2015132619A1/en active Application Filing
- 2014-05-15 JP JP2016513459A patent/JP2016520077A/ja not_active Withdrawn
- 2014-05-15 AU AU2014385320A patent/AU2014385320B2/en active Active
- 2014-05-15 US US14/783,699 patent/US20210145963A9/en not_active Abandoned
- 2014-05-15 CA CA2909586A patent/CA2909586C/en active Active
-
2015
- 2015-11-13 CL CL2015003333A patent/CL2015003333A1/es unknown
-
2016
- 2016-04-18 HK HK16104408.0A patent/HK1216395A1/zh unknown
-
2019
- 2019-05-08 JP JP2019087976A patent/JP2019142962A/ja not_active Withdrawn
-
2020
- 2020-01-10 AU AU2020200216A patent/AU2020200216A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021001926A patent/JP2021059596A/ja active Pending
-
2022
- 2022-02-04 AU AU2022200747A patent/AU2022200747A1/en active Pending
- 2022-03-23 US US17/702,231 patent/US20230098265A1/en not_active Abandoned
- 2022-08-31 JP JP2022137454A patent/JP2022172244A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022172244A5 (ja) | ||
JP2019519252A5 (ja) | ||
JP2017515508A5 (ja) | ||
JP2003526662A5 (ja) | ||
WO2004011650A2 (en) | Antigens encoded by alternative reading frame from pathogenic viruses | |
JP2012503011A5 (ja) | 慢性c型肝炎ウイルス感染症のための酵母系免疫治療組成物 | |
JP2010500399A5 (ja) | ||
JP2008514203A5 (ja) | ||
JP2004518631A5 (ja) | ||
Encke et al. | DNA vaccines | |
JP2014523878A5 (ja) | ||
JP2007505033A5 (ja) | ||
JP2010099084A (ja) | Hiv調節/アクセサリータンパク質の融合タンパク質 | |
JP2009501001A5 (ja) | ||
JP2008539164A5 (ja) | ||
JP2019142962A5 (ja) | ||
JP2009501012A5 (ja) | ||
JP2004527524A5 (ja) | ||
Noordeen | Hepatitis B virus infection: An insight into infection outcomes and recent treatment options | |
Wang et al. | Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen | |
JP2022071130A5 (ja) | ||
JP2006502228A5 (ja) | ||
JP2003508409A (ja) | 慢性ウイルス感染に対するペプチド混合物及びワクチン | |
JP2007504112A5 (ja) | ||
BRPI0414026A (pt) | composição para a prevenção/tratamento de infecções de hbv e doenças mediadas por hbv e método para preparar um medicamento para o tratamento terapêutico de hepatite b |